Ken Griffin Neoleukin Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.68 - $0.91 $32,565 - $43,580	47,891 New	47,891 $39,000
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.25 $54,429 - $133,114	59,162 Added 290.87%	79,502 $82,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $5,273 - $16,035	3,066 Added 17.75%	20,340 $39,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $23,677 - $39,463	-5,092 Reduced 22.77%	17,274 $83,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $71,414 - $114,026	11,804 Added 111.76%	22,366 $161,000
Q2 2021 Aug 16, 2021	SELL	$9.23 - $13.12 $13,558 - $19,273	-1,469 Reduced 12.21%	10,562 $97,000
Q1 2021 May 17, 2021	SELL	$11.26 - $15.78 $403,389 - $565,318	-35,825 Reduced 74.86%	12,031 $148,000
Q4 2020 Feb 16, 2021	SELL	$10.17 - $14.56 $3.22 Million - $4.61 Million	-316,903 Reduced 86.88%	47,856 $675,000
Q3 2020 Nov 16, 2020	BUY	$9.68 - $17.01 $3.02 Million - $5.31 Million	312,026 Added 591.71%	364,759 $4.38 Million
Q2 2020 Aug 14, 2020	SELL	$9.95 - $17.05 $381,920 - $654,447	-38,384 Reduced 42.13%	52,733 $875,000
Q1 2020 May 15, 2020	BUY	$6.12 - $13.64 $557,636 - $1.24 Million	91,117 New	91,117 $1.04 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.